Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 9/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24124368 | 0.89 | PLA2G2C (0.71) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB | |
| SCHEMBL22083015 | 0.85 | PLA2G2C (0.46) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB | |
| SCHEMBL17506705 | 0.83 | TAS1R3 (0.47) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB | |
| SCHEMBL13888611 | 0.83 | TAS1R3 (0.47) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB | |
| SCHEMBL10033481 | 0.83 | TAS1R3 (0.50) | PLA2G2CPLA2G2ATAS1R3TAS1R1 | |
| SCHEMBL13316539 | 0.81 | TAS1R3 (0.46) | PLA2G2CPLA2G2ATAS1R3TAS1R1 | |
| SCHEMBL15780011 | 0.79 | PLA2G2C (0.43) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB | |
| SCHEMBL18221484 | 0.79 | PLA2G2C (0.43) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB | |
| SCHEMBL8367402 | 0.79 | TAS1R3 (0.46) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB | |
| SCHEMBL9005272 | 0.77 | PLA2G2C (0.49) | PLA2G2CPLA2G2ATAS1R3TAS1R1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |